^
Association details:
| Biomarker: | FAT1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
Published date:
06/23/2022
Excerpt:
We collected somatic mutation profiles and clinical information from ICI-treated 631 melanoma and 109 NSCLC samples, respectively….Associations of FAT1 mutations with improved prognosis and ICI response were confirmed in NSCLC patients.
DOI:
https://doi.org/10.1038/s41698-022-00292-6
Source:
Title:
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Published date:
02/25/2022
Excerpt:
...the relationship between FAT1/2/3/4 mutations and efficacy of immunotherapy was explored in the Hellmann cohort consist of patients with NSCLC....Five patient who had mutant FAT1 showed better PFS compared to those with wildtype FAT1 (median, not reached (NR) vs 6.5 months; HR = 0.135; 95% CI: 0.059–0.306; P = .017, Figure 7A). The best overall response (BOR) rates of patients with a mutant FAT1 and those with wildtype FAT1 were 100.0% and 30.0%, respectively (Figure 7B, χ2 = 9.894, P = .001). The durable clinical benefit (DCB) rates of patients with mutant FAT1 and those with wildtype FAT1 were 100.0% and 46.0%, respectively (Figure 5C, χ2 = 5.502, P = .019).
DOI:
https://doi.org/10.1177/10732748221076682
